Zomedica Corp. (NYSEAMERICAN:ZOM - Get Free Report) COO Anthony K. Blair acquired 150,000 shares of the firm's stock in a transaction that occurred on Monday, May 13th. The stock was acquired at an average price of $0.14 per share, for a total transaction of $21,000.00. Following the completion of the transaction, the chief operating officer now directly owns 150,000 shares in the company, valued at $21,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Zomedica Stock Performance
ZOM remained flat at $0.14 during midday trading on Tuesday. 17,053,367 shares of the company's stock were exchanged, compared to its average volume of 5,487,234. Zomedica Corp. has a one year low of $0.12 and a one year high of $0.25. The firm has a market capitalization of $140.23 million, a PE ratio of -3.66 and a beta of 0.99.
Zomedica (NYSEAMERICAN:ZOM - Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $6.26 million for the quarter. Zomedica had a negative return on equity of 8.62% and a negative net margin of 143.67%.
Institutional Trading of Zomedica
A hedge fund recently bought a new stake in Zomedica stock. Sequoia Financial Advisors LLC purchased a new position in shares of Zomedica Corp. (NYSEAMERICAN:ZOM - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 214,949 shares of the company's stock, valued at approximately $43,000. 8.95% of the stock is currently owned by institutional investors.
About Zomedica
(
Get Free Report)
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zomedica wasn't on the list.
While Zomedica currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
